22nd Century Group, Inc.XXII

22nd Century Group Inc told investors on 2 July via an 8-K that it had inked another master-services agreement with a firm whose initials, SF, stand for something fancier than “sell fast.” The document itself is a yawn-boilerplate language about “all addendums”-but the fact that the company is still signing new supply-side deals is the clearest signal that management hasn’t given up on the core business of selling tobacco products, even as the red ink keeps printing. (source: XXII 8-K (2026-07-02), https://www.sec.gov/Archives/edgar/data/1347858/000149315226031964/form8-k.htm)

What 22nd Century actually does is sell reduced-nicotine tobacco through two branded rails-Natural Products and Other Tobacco Products-both of which sit on the same regulatory tightrope as every other cigarette maker: one step forward for public health messaging, two steps sideways for FDA approval timelines. The company’s products are real, the warnings are real, and the images of autumn leaves and harvest moons that adorn the site merely underline that the marketing calendar hasn’t changed even if the lungs have. (source: Natural Products - 22nd Century Group Inc, https://xxiicentury.com/our-brands/natural/; Other Tobacco Products - 22nd Century Group Inc, https://xxiicentury.com/our-brands/other-tobacco-products/)

On paper, the latest 10-Q is a ledger of red: a $3.3 million net loss for the quarter to March 2026, an operating loss of $3.0 million, and diluted EPS of -$18.08 on 595,344 shares. The balance sheet shows $30.3 million in assets against $9.1 million in liabilities, with only $9.5 million of cash and equivalents on hand and operating cash burn of $3.1 million. Inventory crept up $35,000 to $4.3 million-call it a slow-motion clearance sale no one is attending. Capital discipline is visible in the numbers: R&D was $285,000 and capex $40,000, while the board still filed a $20 million buyback programme in the DEF 14A without disclosing any actual repurchases in the year prior. (source: All figures from 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1347858/000168316826004561/0001683168-26-004561-index.htm; DEF 14A (2026-06-23), https://www.sec.gov/Archives/edgar/data/1347858/000149315226029807/formdef14a.htm)

If you want a price chart, head to the SEC EDGAR filings index for 22nd Century Group and scroll to the “Company Facts” JSON; there you’ll find the structured data pipeline that feeds every charting terminal in the world, but the raw filings themselves contain no price, volume, or liquidity metrics-so any candle drawn from public EDGAR data is an artefact, not an insight. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1347858; SEC Company Facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001347855.json)

The S-3 filed on 12 June 2026 is a shelf registration that reads more like a plea for runway than a growth plan: it authorises the sale of unspecified securities “from time to time,” which in small-cap land usually translates to “we need cash and we’re not picky.” The 424B3 prospectus supplement that followed two weeks later is no cheerier: it insists the company is “a tobacco products company with sales and distribution of our own proprietary new reduced nicotine tobacco products,” while the same filing quietly discloses that the only proprietary bit right now is the red ink. (source: S-3 (2026-06-12), https://www.sec.gov/Archives/edgar/data/1347858/000149315226028498/forms-3.htm; 424B3 (2026-06-26), https://www.sec.gov/Archives/edgar/data/1347858/000149315226030296/form424b3.htm)